Company intelligence / Profile preview
HTA Co., Ltd.
Beijing, Chinaen.atom-hitech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HTA has multiple approved diagnostic and therapeutic radiopharmaceutical products, including agents for cancer imaging and treatment as well as cardiac diagnostics. Several programs have reached commercial approval in the EU, Switzerland, and the US since 2016–2017. Additional candidates are in late-stage clinical development.
- Therapeutic areas
- OncologyCardiovascularEndocrinology
- Modalities
- Small molecule drugDiagnostic radiopharmaceuticalsTherapeutic radiopharmaceuticalsPeptide conjugate radionuclide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on HTA Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTA Co., Ltd..